RevenanasBook a free audit

IPO

Windward Bio targets $204M Nasdaq IPO to fund respiratory pipeline

Biotech

IPO

Key Facts

Signal Type

IPO

Industry

Biotech

Companies

Windward Bio, Sanofi, Kelun-Biotech, Harbour BioMed, Qyuns Therapeutics

Date

What Happened

Windward Bio, a Basel-based biotech, filed for an initial public offering on the Nasdaq, planning to offer 10.3 million shares priced between $16 and $18. At the midpoint, net proceeds would be approximately $203.8 million, rising to $228 million if underwriters exercise their option. The company also disclosed a $50 million private placement by Sanofi.

Who Is Affected

The IPO directly impacts Windward Bio, its investors (including Novo Holdings and Sanofi), and its licensing partners Kelun-Biotech, Harbour BioMed, and Qyuns Therapeutics. Competitors in the anti-TSLP space—Amgen, AstraZeneca, Upstream Bio, GSK, Teva, and Uniquity Bio—will face a new publicly funded rival. Vendors of clinical trial management, regulatory affairs, and investor relations software now have a new target account.

Market Impact

The IPO adds a well-capitalized player to the competitive anti-TSLP antibody market, where Amgen/AstraZeneca's Tezspire already holds FDA approval. Windward's lead asset WIN378 is in phase 2 for COPD and phase 2/3 for asthma, while its bispecific WIN027 targets both TSLP and IL-13. The company's $200 million Series A and $165 million Series B, plus this IPO, signal strong investor confidence in the TSLP mechanism.

  • Windward expects to spend up to $227.5 million on WIN378 studies, including a phase 3 asthma trial launching in H1 2027.
  • Up to $85 million is earmarked for WIN027's phase 2b COPD trial and a phase 2 atopic dermatitis study.
  • Sanofi's $50 million private placement provides additional validation and capital.

What to Watch

Watch for the final IPO pricing and whether underwriters exercise their option, which would bring total proceeds to $228 million. Also monitor Windward's ability to execute its phase 3 asthma trial and the competitive responses from Tezspire, verekitug, and other anti-TSLP candidates. The company's preclinical bispecific programs targeting type 2 and non-type 2 inflammatory pathways could expand its pipeline beyond respiratory diseases.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner